Panic Disorder Market

Market Overview:

The 7 major panic disorder markets are expected to exhibit a CAGR of 2.73% during 2024-2034.

The panic disorder market has been comprehensively analyzed in IMARC's new report titled "Panic Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Panic disorder is a type of anxiety that causes recurrent and unexpected panic attacks. These attacks are characterized by a sudden episode of fear or discomfort as well as a sense of loss of control, even when there is no apparent danger or trigger. The ailment can lead to significant impairment in daily functioning and interfere with relationships, work, and other aspects of life. Individuals suffering from this disease may experience physical symptoms, such as a racing heartbeat, sweating, shaking, weakness, nausea, chills, dizziness, difficulty breathing, chest pain, etc. The other common indications include intense terror, a choking or smothering sensation, behavioral changes, fear of losing control, persistent concern, feelings of unreality, depersonalization, etc. The diagnosis of the ailment typically requires a combination of the patient's symptoms and medical history. To be diagnosed with this condition, an individual must meet the diagnostic and statistical manual of mental disorders (DSM-5) criteria, including having at least one frequent panic attack to be followed by a month or more. Also, the attacks must not be caused by substance use or other medical health illnesses.

The increasing prevalence of inherited mental disorders that result in alterations in the way different areas of the brain function is primarily driving the panic disorder market. Moreover, the rising incidences of several associated risk factors, such as major life stress, traumatic events, smoking, excessive caffeine intake, a history of childhood sexual or physical abuse, etc., are further augmenting the market growth. Besides this, the escalating utilization of medications, including selective serotonin reuptake inhibitors and benzodiazepines, to help reduce symptoms and the frequency of attacks in patients is also creating a positive outlook for the market. Additionally, numerous key players are making extensive investments in research activities to launch novel mind-calming and relaxation techniques for treating the ailment, which can reduce muscle tension and stabilize breathing. This, in turn, is acting as another significant growth-inducing factor. Furthermore, the emerging popularity of psychotherapies, such as cognitive-behavioral therapy (CBT) and exposure therapy, since they assist patients in identifying and replacing unhealthy emotions, behaviors, and thoughts with more adaptive ones, is expected to drive the panic disorder market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the panic disorder market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for panic disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the panic disorder market in any manner.

Key Highlights:

• The lifetime prevalence of panic disorder in U.S. adults ranges from 2.0% to 6.0%.
• The 12-month frequency in adults is 2.7%, with 44.8% categorized as severe cases.
• The lifetime prevalence rates of serious depression in panic disorder might be as high as 50-60%.
• Asthma has been related to a 4.5-fold increase in the likelihood of developing panic disorder, and those with panic disorder are 6 times more likely to develop asthma than those without anxiety disorders.
• Women are two to three times as likely to be affected than men.
• The prevalence of panic disorder is low before the age of 14 (<0.4%).

Drugs:

Paxil (Paroxetine) is a selective serotonin reuptake inhibitor (SSRI) developed by Novo Nordisk for the treatment of panic disorder. It is a structural analog of femoxetine. Paxil works by boosting the quantity of serotonin, a naturally occurring neurotransmitter in the brain.

Klonopin (clonazepam) is a drug used to prevent and treat panic disorders. It is a long-acting tranquilizer of the benzodiazepine class. It has anxiolytic, anticonvulsant, sedative, hypnotic, and skeletal muscle relaxing effects. It is normally taken orally (swallowed), although it can also be administered intravenously. The effects begin within one hour and persist between eight and twelve hours in adults.

CVL-865 is under clinical development by Cerevel Therapeutics for the treatment of panic disorder. It is given orally as a tablet. The therapeutic candidate overcomes the notable adverse effects linked to alpha 1 binding by selectively targeting the alpha 2, 3, and 5 subunits of the GABA-A receptor.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the panic disorder market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the panic disorder market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current panic disorder marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the panic disorder market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the panic disorder market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the panic disorder market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of panic disorder across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of panic disorder by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of panic disorder by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with panic disorder across the seven major markets?
• What is the size of the panic disorder patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of panic disorder?
• What will be the growth rate of patients across the seven major markets?
   

Panic Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for panic disorder drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the panic disorder market?
• What are the key regulatory events related to the panic disorder market?
• What is the structure of clinical trial landscape by status related to the panic disorder market?
• What is the structure of clinical trial landscape by phase related to the panic disorder market?
• What is the structure of clinical trial landscape by route of administration related to the panic disorder market?